SUBSCRIBE
SUBSCRIBE
BioCapital

US FDA Tells ADHD Makers To Warn Patients Of Risks

February 21, 2007 | 
1 min read

WASHINGTON, Feb 21 (Reuters) - Manufacturers of attention deficit drugs should alert patients to possible cardiovascular and psychiatric risks from the medicines, U.S. health officials said on Wednesday.>>> Discuss This Story

Johnson & Johnson Family of Companies Eli Lilly and Company Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto
Policy
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease
April 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3d illustration of hepatitis B viruses i
Drug Development
Altimmune Axes Hepatitis B Program After Phase II Failure, Focuses on Obesity and MASH
March 28, 2024
 · 
1 min read
 · 
Tyler Patchen